WO2015158204A1 - 酰胺类衍生物及其可药用盐、其制备方法及其在医药上的应用 - Google Patents
酰胺类衍生物及其可药用盐、其制备方法及其在医药上的应用 Download PDFInfo
- Publication number
- WO2015158204A1 WO2015158204A1 PCT/CN2015/075531 CN2015075531W WO2015158204A1 WO 2015158204 A1 WO2015158204 A1 WO 2015158204A1 CN 2015075531 W CN2015075531 W CN 2015075531W WO 2015158204 A1 WO2015158204 A1 WO 2015158204A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- mmol
- compound
- mixture
- alkyl
- Prior art date
Links
- 0 CCCC*(CCCC(*)C(NC1=*C(CC(C)(CCC(C)(C)C2)*(C)*)C2*=B1)=O)CNC(*)=O Chemical compound CCCC*(CCCC(*)C(NC1=*C(CC(C)(CCC(C)(C)C2)*(C)*)C2*=B1)=O)CNC(*)=O 0.000 description 5
- CPODMFFOZLYDTL-UHFFFAOYSA-N CC(C)(C(NCc1cc(C(Cl)=O)c(C(F)F)nc1)=O)F Chemical compound CC(C)(C(NCc1cc(C(Cl)=O)c(C(F)F)nc1)=O)F CPODMFFOZLYDTL-UHFFFAOYSA-N 0.000 description 2
- GQFKAXSZAMNAIM-UHFFFAOYSA-N CC(C)(C(NCc1cc(C(O)=O)c(C(F)F)nc1)=O)F Chemical compound CC(C)(C(NCc1cc(C(O)=O)c(C(F)F)nc1)=O)F GQFKAXSZAMNAIM-UHFFFAOYSA-N 0.000 description 2
- MDVPHODXRFXXKQ-UHFFFAOYSA-N CC[n]1c(-c(cc2)ccc2Cl)nc2c1ccc(N)c2 Chemical compound CC[n]1c(-c(cc2)ccc2Cl)nc2c1ccc(N)c2 MDVPHODXRFXXKQ-UHFFFAOYSA-N 0.000 description 2
- FVFFBSMJPITPJY-UHFFFAOYSA-N CC[n]1c(-c(cc2)ccc2Cl)nc2c1ccc(NC(c1cc(CNC(C(C)C)=O)cnc1C(F)F)=O)c2 Chemical compound CC[n]1c(-c(cc2)ccc2Cl)nc2c1ccc(NC(c1cc(CNC(C(C)C)=O)cnc1C(F)F)=O)c2 FVFFBSMJPITPJY-UHFFFAOYSA-N 0.000 description 2
- YHSPOCHEGHGPCN-UHFFFAOYSA-N CC(C)C(NCc1cc(C(O)=O)c(C(F)F)nc1)=O Chemical compound CC(C)C(NCc1cc(C(O)=O)c(C(F)F)nc1)=O YHSPOCHEGHGPCN-UHFFFAOYSA-N 0.000 description 1
- UBSDYNGRFUAKPG-UHFFFAOYSA-N CC[n](c(-c1cc(Cl)ccc1)c1)c(cc2)c1nc2Cl Chemical compound CC[n](c(-c1cc(Cl)ccc1)c1)c(cc2)c1nc2Cl UBSDYNGRFUAKPG-UHFFFAOYSA-N 0.000 description 1
- XEOQFGZVIQXFLO-UHFFFAOYSA-N CC[n](c(-c1cc(Cl)ccc1)c1)c(cc2)c1nc2N Chemical compound CC[n](c(-c1cc(Cl)ccc1)c1)c(cc2)c1nc2N XEOQFGZVIQXFLO-UHFFFAOYSA-N 0.000 description 1
- OSNVMTSRFZDTBL-UHFFFAOYSA-N CC[n](c(-c1ccc(C(F)(F)F)cc1)c1)c(cc2)c1cc2NC(c1c(C(F)F)ncc(CNC(C(C)C)=O)c1)=O Chemical compound CC[n](c(-c1ccc(C(F)(F)F)cc1)c1)c(cc2)c1cc2NC(c1c(C(F)F)ncc(CNC(C(C)C)=O)c1)=O OSNVMTSRFZDTBL-UHFFFAOYSA-N 0.000 description 1
- DBBHVZPHBJJNSU-UHFFFAOYSA-N CC[n]1c2ccc(N=C(c3ccccc3)c3ccccc3)nc2cc1-c1cc(Cl)ccc1 Chemical compound CC[n]1c2ccc(N=C(c3ccccc3)c3ccccc3)nc2cc1-c1cc(Cl)ccc1 DBBHVZPHBJJNSU-UHFFFAOYSA-N 0.000 description 1
- DXPCSEBCKXUVMV-UHFFFAOYSA-N CC[n]1c2ccc(NC(c3c(C(F)F)ncc(CNC(C(C)(C)F)=O)c3)=O)nc2cc1-c1cccc(Cl)c1 Chemical compound CC[n]1c2ccc(NC(c3c(C(F)F)ncc(CNC(C(C)(C)F)=O)c3)=O)nc2cc1-c1cccc(Cl)c1 DXPCSEBCKXUVMV-UHFFFAOYSA-N 0.000 description 1
- OAJXKCRGMPNUPO-UHFFFAOYSA-N C[ClH]c(cc1)ccc1[IH]C Chemical compound C[ClH]c(cc1)ccc1[IH]C OAJXKCRGMPNUPO-UHFFFAOYSA-N 0.000 description 1
- MURSLIZLMVUHNV-UHFFFAOYSA-N Clc1cccc(-c2cc(nc(cc3)Cl)c3[nH]2)c1 Chemical compound Clc1cccc(-c2cc(nc(cc3)Cl)c3[nH]2)c1 MURSLIZLMVUHNV-UHFFFAOYSA-N 0.000 description 1
- FLUVCYLGGOSDAP-UHFFFAOYSA-N Nc(cc1)cc2c1[n](C1COCC1)c(-c(cc1)ccc1Cl)c2 Chemical compound Nc(cc1)cc2c1[n](C1COCC1)c(-c(cc1)ccc1Cl)c2 FLUVCYLGGOSDAP-UHFFFAOYSA-N 0.000 description 1
- IQYZYNICIBQOJB-UHFFFAOYSA-N O=Nc(cc1)cc2c1[nH]c(-c(cc1)ccc1Cl)c2 Chemical compound O=Nc(cc1)cc2c1[nH]c(-c(cc1)ccc1Cl)c2 IQYZYNICIBQOJB-UHFFFAOYSA-N 0.000 description 1
- LDJCAMUVZBTVOE-WYMLVPIESA-N [O-][N+](c1cc(C=C/C(/CC2)=C3/COCC3)c2cc1)=O Chemical compound [O-][N+](c1cc(C=C/C(/CC2)=C3/COCC3)c2cc1)=O LDJCAMUVZBTVOE-WYMLVPIESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/44—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Definitions
- the present invention relates to a novel class of amide derivatives, a process for the preparation thereof, and a pharmaceutical composition containing the same, and the use thereof as a therapeutic agent, particularly as a microsomal prostaglandin E synthetase-1 (mPGES-1) inhibitor And use in the manufacture of a medicament for the treatment and/or prevention of a disease or condition such as inflammation and/or pain.
- mPGES-1 microsomal prostaglandin E synthetase-1
- Inflammatory diseases affecting people include asthma, inflammatory bowel disease, rheumatoid arthritis, osteoarthritis, rhinitis, conjunctivitis and dermatitis. Inflammation is also a common cause of pain, which can be caused by a variety of causes, such as infections, surgery or other trauma. At the same time, some diseases including malignant tumors and cardiovascular diseases also have symptoms of inflammation.
- Prostaglandin E2 is one of the most common prostaglandins (PG). It is a strong pro-inflammatory mediator that induces fever and pain and participates in various physiological and pathophysiological processes. Its chemical synthesis consists of three consecutive enzymatic reactions: (1) arachidonic acid (AA) is liberated from phospholipids on the membrane by phospholipase A2 (PLA2); (2) AA produces PGG2 and PGH2 under the action of cyclooxygenase (COX); (3) PGE2 synthase (PGES) catalyzes PGH2 production of PGE2, PGF2, PGD2, prostacyclin and thromboxane A2.
- AA arachidonic acid
- PAG2 phospholipase A2
- COX cyclooxygenase
- PGES PGE2 synthase
- COX cyclooxygenase
- COX-1 and/or COX-2 inhibitors have been shown to inhibit inflammation by ultimately reducing PGE2 formation, such as "NSAID” (non-steroidal anti-inflammatory drugs) and "coxib” (selective COX-2 inhibitors).
- NSAID non-steroidal anti-inflammatory drugs
- coxib selective COX-2 inhibitors
- target COX reduces the formation of all metabolites of arachidonic acid (AA), which contain beneficial ingredients for the human body, so COX inhibitors may have adverse biological effects on the human body. Therefore, the development of new drugs that are safer and more effective for inflammatory diseases has great clinical significance and market value.
- the enzyme system PGES that directly targets PGE2 synthesis is the terminal rate-limiting enzyme in the PGE2 synthesis process.
- PGES cytosolic PGES
- PGES-3 membrane-bound PGES-1
- mPGES-2 membrane-bound PGES-2
- cPGES is a GSH-dependent constitutive enzyme, an enzyme widely expressed in various tissues and cells by housekeeping genes, and is not affected by inflammatory stimulators.
- mPGES-2 is a GSH-independent constitutive enzyme mainly expressed in tissues with relatively low expression of mPGES-1, such as brain, heart, kidney, small intestine, etc., and is not induced by tissue inflammation and damage.
- mPGES-1 is a GSH-dependent inducible expression of an enzyme that can be expressed by proinflammatory cytokines and expressed in large quantities in pathophysiological processes in various diseases such as arthritis, inflammation-related fever and pain, atherosclerosis and cancer. Focus on To be effective.
- the human mPGES-1 gene is located on chromosome 9q34.3 and comprises three exons and two introns, approximately 14.8 kb in length, and the cDNA encodes a polypeptide of 152 amino acids.
- the primary structure of the mPGES-1 protein of different species has more than 80% homology.
- mPGES-1 inhibitors are AAD-2004 from Korea GNT (Neurotech) and LY-3023703 from Eli Lilly.
- AAD-2004 is not for pain, but a potent spin-trapping molecule and microsomal prostaglandin E synthase-1 inhibitor for the treatment of Alzheimer's disease, Parkinson's disease and motor neuron disease.
- LY-3023703 was used to treat osteoarthritis pain. It entered the first phase of clinical trial in June 2012. So far, Eli Lilly's mPGES-1 project has only published two patents WO2012087771 and WO2012161965.
- microsomal prostaglandin E synthetase-1 (mPGES-1) inhibitors have been disclosed, there is still a need to develop new compounds with better pharmacodynamics, and the design of the present invention has a general formula through continuous efforts.
- the compound of the structure shown in (I), and the compound having such a structure was found to exhibit excellent effects and effects.
- the object of the present invention is to provide a compound of the formula (I) or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer thereof, or In the form of a mixture, or a pharmaceutically acceptable salt thereof:
- Ring P is selected from a 5-membered heteroaryl group and a 5-membered heterocyclic group
- Ring Q is selected from aryl or heteroaryl, preferably phenyl, pyridyl or pyrimidinyl;
- A, B or Y is selected from -CH- or N;
- R 1 is selected from alkyl or cycloalkyl, wherein said alkyl or cycloalkyl is optionally further substituted with one or more substituents selected from alkyl, halo or haloalkyl;
- R 2 is selected from halogen or haloalkyl
- Each R 3 is the same or different and is each independently selected from the group consisting of a hydrogen atom, a halogen, an alkoxy group, a cyano group, a nitro group, an alkyl group, a cycloalkyl group, a heterocyclic group, an oxo group, a -C(O)OR 5 group , -OC(O)R 5 , -NHS(O) m R 5 , -C(O)R 5 , -NHC(O)R 5 , -NHC(O)OR 5 , -NR 6 R 7 , -OC( Or) NR 6 R 7 or -C(O)NR 6 R 7 wherein said alkyl, cycloalkyl or heterocyclic group is further optionally further selected from one or more selected from the group consisting of halogen, hydroxy, alkoxy and cyanide Base, nitro, alkyl, haloalkyl, hydroxyalkyl, cycloalky
- R 4 is selected from aryl or heteroaryl, preferably phenyl, wherein said aryl or heteroaryl is optionally further further selected from one or more selected from the group consisting of halogen, alkoxy, hydroxy, cyano, nitro, Alkyl, haloalkyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(O)OR 5 , -OC(O)R 5 , -NHS(O) m R 5 , -C(O)R 5 , -NHC(O)R 5 , -NHC(O)OR 5 , -NR 6 R 7 , -OC(O)NR 6 R 7 or -C(O)NR 6 R 7 Substituted by a substituent, wherein the haloalkyl group is preferably a trifluoromethyl group;
- R 5 is selected from alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said alkyl, cycloalkyl, aryl or heteroaryl group is optionally further Or substituted with a plurality of substituents selected from the group consisting of alkyl, halogen, hydroxy, hydroxyalkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxylic acid or carboxylic acid esters;
- R 6 or R 7 are each independently selected from a hydrogen atom, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, the alkoxy group, the cycloalkyl group,
- the heterocyclyl, aryl or heteroaryl are each independently optionally further selected from one or more selected from the group consisting of alkyl, halo, hydroxy, hydroxyalkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, hetero Substituted by a substituent of an aryl group, a carboxylic acid or a carboxylic acid ester;
- R 6 or R 7 together with a nitrogen atom to which they are attached form a heterocyclic group, wherein said heterocyclic group contains one or more N, O or S(O) m heteroatoms, and said heterocyclic group Optionally further substituted by one or more substituents selected from the group consisting of alkyl, halo, hydroxy, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxylic acid or carboxylic acid esters Replace
- n 0, 1 or 2;
- s is an integer from 0 to 3;
- t 0 or 1.
- a preferred embodiment of the invention a compound of the formula (I) or a tautomer, a mesophil, a racemate, an enantiomer, a diastereomer thereof, or In the form of a mixture, or a pharmaceutically acceptable salt thereof, wherein t is 1 when R 2 is a halogen.
- a preferred embodiment of the invention a compound of the formula (I) or a tautomer, a mesophil, a racemate, an enantiomer, a diastereomer thereof, or a mixture, or a pharmaceutically acceptable salt thereof, which is a compound of the formula (II) or a tautomer, a mesogen, a racemate, an enantiomer, a diastereomer a conformation, or a mixture thereof, or a pharmaceutically acceptable salt thereof:
- X is selected from -CH- or N;
- the ring P, A, B, Y, s, t, R 1 to R 4 are as defined in the formula (I).
- a preferred embodiment of the invention a compound of the formula (I) or a tautomer, a mesophil, a racemate, an enantiomer, a diastereomer thereof, or a mixture, or a pharmaceutically acceptable salt thereof, which is a compound of the formula (III), (IV) or (V) or a tautomer, a mesogen, a racemate, an antipode Isomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts thereof:
- X is selected from -CH- or N;
- E, G and W are each independently selected from CR a , NR b , N, O or S;
- R a and R b are each independently selected from a hydrogen atom, a halogen, an alkoxy group, a cyano group, a nitro group, an alkyl group, a cycloalkyl group, a heterocyclic group, -C(O)OR 5 , -OC(O)R.
- alkyl, cycloalkyl or heterocyclic group is optionally further selected from one or more halogen, hydroxy, alkoxy, cyano, nitro, alkyl , haloalkyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(O)OR 5 , -OC(O)R 5 , -NHS(O) m R 5 , -C (O) a substituent of R 5 , -NHC(O)R 5 , -NHC(O)OR 5 , -NR 6 R 7 , -OC(O)NR 6 R 7 or -C(O)
- A, B, Y, t, R 1 to R 2 and R 4 to R 7 are as defined in the formula (I).
- a preferred embodiment of the invention a compound of the formula (I) or a tautomer, a mesophil, a racemate, an enantiomer, a diastereomer thereof, or a mixture, or a pharmaceutically acceptable salt thereof, which is a compound of the formula (VI) or a tautomer, a mesogen, a racemate, an enantiomer, a diastereomer a conformation, or a mixture thereof, or a pharmaceutically acceptable salt thereof:
- X is selected from -CH- or N;
- R b is selected from the group consisting of a hydrogen atom, a halogen, an alkoxy group, a cyano group, a nitro group, an alkyl group, a cycloalkyl group, a heterocyclic group, -C(O)OR 5 , -OC(O)R 5 , -NHS(O m R 5 , -C(O)R 5 , -NHC(O)R 5 , -NHC(O)OR 5 , -NR 6 R 7 , -OC(O)NR 6 R 7 or -C(O) NR 6 R 7 wherein said alkyl, cycloalkyl or heterocyclic group is further optionally further selected from one or more selected from the group consisting of halogen, hydroxy, alkoxy, cyano, nitro, alkyl, haloalkyl, hydroxy Alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(O
- A, B, Y, t, R 1 to R 2 and R 4 to R 7 are as defined in the formula (I).
- a preferred embodiment of the invention a compound of the formula (I) or a tautomer, a mesophil, a racemate, an enantiomer, a diastereomer thereof, or a mixture, or a pharmaceutically acceptable salt thereof, which is a compound of the formula (VII) or a tautomer, a mesogen, a racemate, an enantiomer, a diastereomer a conformation, or a mixture thereof, or a pharmaceutically acceptable salt thereof:
- X is selected from -CH- or N;
- R b is selected from the group consisting of a hydrogen atom, a halogen, an alkoxy group, a cyano group, a nitro group, an alkyl group, a cycloalkyl group, a heterocyclic group, -C(O)OR 5 , -OC(O)R 5 , -NHS(O m R 5 , -C(O)R 5 , -NHC(O)R 5 , -NHC(O)OR 5 , -NR 6 R 7 , -OC(O)NR 6 R 7 or -C(O) NR 6 R 7 wherein said alkyl, cycloalkyl or heterocyclic group is further optionally further selected from one or more selected from the group consisting of halogen, hydroxy, alkoxy, cyano, nitro, alkyl, haloalkyl, hydroxy Alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(O
- R 8 is selected from the group consisting of halogen, alkoxy, hydroxy, cyano, nitro, alkyl, haloalkyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(O)OR 5 , -OC(O)R 5 , -NHS(O) m R 5 , -C(O)R 5 , -NHC(O)R 5 , -NHC(O)OR 5 , -NR 6 R 7 , -OC Substituted by a substituent of (O)NR 6 R 7 or -C(O)NR 6 R 7 wherein said haloalkyl group is preferably a trifluoromethyl group;
- A, B, Y, R 1 to R 2 and R 5 to R 7 are as defined in the formula (I).
- a preferred embodiment of the invention a compound of the formula (VII) or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer thereof, or a mixture, or a pharmaceutically acceptable salt thereof, which is a compound of the formula (VII-A), (VII-B) or a tautomer, a mesogen, a racemate, an antipode Isomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts thereof:
- A, B, X, Y, R 1 to R 2 , R 8 and R b are as defined in the formula (VII).
- a preferred embodiment of the invention a compound of the formula (I) or a tautomer, a mesogen, a racemate, an enantiomer, a diastereomer thereof, and a mixture form, and a pharmaceutically acceptable salt thereof, wherein A, B and Y are selected from CH.
- a preferred embodiment of the invention a compound of the formula (I) or a tautomer thereof, a mesogen, a racemate, an enantiomer, a diastereomer, a mixture thereof, and a pharmaceutically acceptable salt thereof, wherein one of A, B and Y is N and the other two are -CH-.
- a preferred embodiment of the invention a compound of the formula (I) or a tautomer, a mesophil, a racemate, an enantiomer, a diastereomer thereof, or a mixture, or a pharmaceutically acceptable salt thereof, wherein the group
- R 3 and R 4 are as defined in the formula (I).
- a compound of the formula (I) or a tautomer, a mesophil, a racemate, an enantiomer or a diastereomer thereof, Or a mixture thereof, or a pharmaceutically acceptable salt thereof is provided.
- R 1 is selected from alkyl or haloalkyl, preferably t-butyl, isopropyl,
- a compound of the formula (I) or a tautomer, a mesophil, a racemate, an enantiomer or a diastereomer thereof, Or a mixture thereof, or a pharmaceutically acceptable salt thereof is provided.
- R 1 is selected from cycloalkyl, wherein cycloalkyl is further substituted by haloalkyl, and R 1 is preferably
- Typical compounds of the invention include, but are not limited to:
- a tautomer a meso form, a racemate, an enantiomer, a diastereomer, or a mixture thereof, or a pharmaceutically acceptable salt thereof.
- the present invention also provides a compound of the formula (I) or a tautomer, a mesophil, a racemate, an enantiomer, a diastereomer, or a mixture thereof. a method of form, or a pharmaceutically acceptable salt thereof, the method comprising:
- a compound of the formula (I) or a salt thereof is subjected to a condensation reaction with a compound of the formula (IB) under basic conditions to give a compound of the formula (I);
- R c is selected from a hydroxyl group or a halogen
- the ring P, ring Q, A, B, Y, s, t, R 1 to R 4 are as defined in the formula (I).
- the alkaline conditions include organic bases and inorganic bases including, but not limited to, triethylamine, N,N-diisopropylethylamine, pyridine, hexamethyldisilazide sodium. , n-butyllithium, potassium t-butoxide or tetrabutylammonium bromide, the inorganic bases include, but are not limited to, lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium hydride, sodium carbonate, sodium hydrogencarbonate, Potassium carbonate, potassium hydrogencarbonate or cesium carbonate, preferably triethylamine.
- Catalysts include, but are not limited to, palladium on carbon, Raney nickel.
- Condensing agents include, but are not limited to, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N'-dicyclohexylcarbodiimide, N,N'-di Propylcarbodiimide, O-benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroborate, 1-hydroxybenzotriazole, 1-hydroxy-7- Azobenzotriazole, O-benzotriazole-N,N,N',N'-four Methylurea hexafluorophosphate, 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, benzotriazole-1-yloxy Tris(dimethylamino)phosphonium hexafluorophosphate or benzotriazol-1-yl-oxytripyrrolidin
- the present invention also provides a compound of the formula (IA) or a tautomer, a mesophil, a racemate, an enantiomer, a diastereomer, or a mixture thereof. , or a pharmaceutically acceptable salt thereof:
- R 3 is selected from a hydrogen atom, an alkyl group or a heterocyclic group, wherein the alkyl group is optionally further substituted by one or more substituents selected from alkoxy or heterocyclic groups; preferably a C 1 -C 4 alkane a group, a C 1 -C 4 alkoxy group or a tetrahydrofuranyl group;
- R 4 is selected from aryl or heteroaryl, wherein said aryl or heteroaryl is optionally further substituted by one or more substituents selected from halogen or haloalkyl, wherein said haloalkyl is preferably three a fluoromethyl group; R 4 is preferably a phenyl group, wherein the phenyl group is further substituted with a halogen or a halogenated alkyl group;
- t 1;
- R 3 is selected from a hydrogen atom or an alkyl group, wherein the alkyl group is optionally further substituted with one or more substituents selected from alkoxy or heterocyclic groups;
- R 4 is selected from phenyl, wherein said phenyl group is further substituted with a substituent of a haloalkyl group; wherein said haloalkyl group is preferably a trifluoromethyl group;
- R 3 is selected from a heterocyclic group
- R 4 is selected from phenyl, wherein the phenyl group is further substituted with a substituent of a halogen or a haloalkyl group.
- the compound represented by the formula (IA) includes, but is not limited to:
- a tautomer a meso form, a racemate, an enantiomer, a diastereomer, or a mixture thereof, or a pharmaceutically acceptable salt thereof.
- the present invention also provides a compound represented by the formula (IB) or a tautomer, a mesophil, a racemate, an enantiomer, a diastereomer, or a mixture thereof. , or a pharmaceutically acceptable salt thereof:
- R c is selected from a hydroxyl group or a halogen
- the ring Q, R 1 and R 2 are as defined in the formula (I).
- the compound represented by the formula (IB) includes, but is not limited to:
- a tautomer a meso form, a racemate, an enantiomer, a diastereomer, or a mixture thereof, or a pharmaceutically acceptable salt thereof.
- the invention further relates to a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula (I) or a tautomer thereof, a mesogen, a racemate, an enantiomer Isomers, diastereomers, or mixtures thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
- the invention further relates to a compound of the formula (I) or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, or a mixture thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof
- a pharmaceutical composition for the preparation of a medicament for treating a microsomal prostaglandin E synthetase-1 (mPGES-1) mediated disease.
- the invention further relates to a compound of the formula (I) or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, or a mixture thereof, or Use of a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, for the preparation of a medicament for inhibiting microsomal prostaglandin E synthetase-1 (mPGES-1).
- mPGES-1 microsomal prostaglandin E synthetase-1
- the invention further relates to a compound of the formula (I) or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, or a mixture thereof, or Use of a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, for the manufacture of a medicament for treating or preventing a disease or condition, including inflammation, pain, cancer, diabetes and diabetic complications or neurodegenerative disorders
- the inflammation includes an autoimmune disease associated with inflammation, a skin disease, a lung disease, a visceral condition, an oropharyngeal or oropharyngeal disease, or a cardiovascular disease, wherein the autoimmune diseases include arthritis, osteoarthritis, juvenile arthritis.
- rheumatoid arthritis ankylosing spondylitis, gout, rheumatic fever, bursitis, systemic lupus erythematosus or multiple sclerosis
- skin diseases including dermatitis, eczema, psoriasis, burns or tissue trauma
- lung diseases including asthma, Chronic obstructive pulmonary disease or pulmonary fibrosis
- visceral disorders including inflammatory bowel disease, Crohn's disease, ulcerative colitis, irritating bowel syndrome, gastric ulcer, bladder , prostatitis, pancreatitis or nephritis
- ear, nose and oropharyngeal diseases including influenza, viral infections, bacterial infections, fever, rhinitis, pharyngitis, tonsillitis, conjunctivitis, ulceris, scleritis or uveitis
- Vascular diseases include atherosclerosis, thrombosis, stroke or coronary heart disease; the pain includes neur
- the invention also relates to a method of treating a microsomal prostaglandin E synthetase-1 (mPGES-1) mediated disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or An isomer, a meso form, a racemate, an enantiomer, a diastereomer, or a mixture thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same.
- mPGES-1 microsomal prostaglandin E synthetase-1
- the present invention also relates to a method for inhibiting the activity of microsomal prostaglandin E synthetase-1 (mPGES-1) comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the formula (I) or tautomerism thereof. a form, a meso form, a racemate, an enantiomer, a diastereomer, or a mixture thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same.
- mPGES-1 microsomal prostaglandin E synthetase-1
- the invention relates to a method of treating or preventing a disease or condition comprising administering a desired condition A therapeutically effective amount of a compound of the formula (I) or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, or a mixture thereof, Or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, the disease or condition comprising inflammation, pain, cancer, diabetes and diabetic complications or neurodegenerative disorders, etc., wherein the inflammation comprises autoimmunity associated with inflammation Sexual diseases, skin diseases, lung diseases, visceral diseases, oropharyngeal or oropharyngeal diseases or cardiovascular diseases, among which autoimmune diseases include arthritis, osteoarthritis, juvenile arthritis, rheumatoid arthritis, ankylosing spondylitis, Gout, rheumatic fever, bursitis, systemic lupus erythematosus or multiple sclerosis; skin diseases including dermatitis, e
- the present invention also relates to a compound of the formula (I) or a tautomer, a mesophil, a racemate, an enantiomer, a diastereomer, or a mixture thereof, or A pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, as a medicament for treating a microsomal prostaglandin E synthetase-1 (mPGES-1) mediated disease.
- mPGES-1 microsomal prostaglandin E synthetase-1
- the present invention also relates to a compound of the formula (I) or a tautomer, a mesophil, a racemate, an enantiomer, a diastereomer, or a mixture thereof, or A pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, which is a medicament for inhibiting the activity of microsomal prostaglandin E synthetase-1 (mPGES-1).
- mPGES-1 microsomal prostaglandin E synthetase-1
- the present invention also relates to a compound of the formula (I) or a tautomer, a mesophil, a racemate, an enantiomer, a diastereomer, or a mixture thereof, or A pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, which is a medicament for treating or preventing a disease or a condition, including inflammation, pain, cancer, diabetes and diabetic complications or neurodegenerative diseases, and the like, wherein
- the inflammation includes an autoimmune disease associated with inflammation, a skin disease, a lung disease, a visceral condition, an otolaryngeal or oropharyngeal disease, or a cardiovascular disease, wherein the autoimmune diseases include arthritis, osteoarthritis, juvenile arthritis, and the like.
- Rheumatoid arthritis ankylosing spondylitis, gout, rheumatic fever, bursitis, systemic lupus erythematosus or multiple sclerosis
- skin diseases including dermatitis, eczema, psoriasis, burns or tissue trauma
- lung diseases including asthma, chronic obstruction Pulmonary disease or pulmonary fibrosis
- visceral disorders include inflammatory bowel disease, Crohn's disease, ulcerative colitis, irritating bowel syndrome, gastric ulcer, cystitis, prostatitis, pancreatitis or nephritis
- Pharyngeal diseases include influenza, viral infections, bacterial infections, fever, rhinitis, pharyngitis, tonsillitis, conjunctivitis, ulceris, scleritis or uveitis
- cardiovascular diseases including atherosclerosis, thrombosis, stroke Or coronary heart disease, etc.
- the pain includes neuropathic pain, inflammatory pain
- Alkyl means a saturated aliphatic hydrocarbon group, including straight chain and branched chain groups of 1 to 20 carbon atoms. An alkyl group having 1 to 10 carbon atoms is preferred, and an alkyl group having 1 to 6 carbon atoms is more preferred.
- Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2 -methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1, 3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl,
- lower alkyl groups having from 1 to 6 carbon atoms, non-limiting examples including methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl Base, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethyl Butyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl Base, 2,3-dimethylbutyl and the like.
- the alkyl group may be substituted or unsubstituted, and when substituted, the substituent may be substituted at any available point of attachment, preferably one or more of the following groups, independently selected from alkyl, alkenyl, Alkynyl, alkoxy, alkylthio, alkylamino, halogen, sulfhydryl, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycle Alkoxy, cycloalkylthio, heterocycloalkylthio, oxo, amino, haloalkyl, hydroxyalkyl, carboxyl, carboxylate, -C(O)OR 5 , -OC(O)R 5 , -NHS(O) m R 5 , -C(O)R 5 , -NHC(O)R 5 , -NHC(O)OR 5 , -NR 6 R 7 ,
- alkenyl refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, such as ethenyl, 1-propenyl, 2-propenyl, 1-, 2- or -butenyl and the like.
- a C 2-10 alkenyl group is preferred, a C 2-6 alkenyl group is more preferred, and a C 2-4 alkenyl group is most preferred.
- the alkenyl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, Alkylamino, halogen, sulfhydryl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, hetero Cycloalkylthio, oxo, amino, haloalkyl, hydroxyalkyl, carboxylic acid, carboxylate, -C(O)OR 5 , -OC(O)R 5 , -NHS(O) m R 5 , -C(O)R 5 , -NHC(O)R 5 , -NHC(O)OR 5 , -NR 6 R 7 ,
- alkynyl refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon triple bond, such as ethynyl, 1-propynyl, 2-propynyl, 1-, 2- Or 3-butynyl and the like.
- a C 2-10 alkynyl group is preferred, a C 2-6 alkynyl group is more preferred, and a C 2-4 alkynyl group is most preferred.
- the alkynyl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, Alkylamino, halogen, sulfhydryl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, hetero Cycloalkylthio, oxo, amino, haloalkyl, hydroxyalkyl, carboxylic acid, carboxylate, -C(O)OR 5 , -OC(O)R 5 , -NHS(O) m R 5 , -C(O)R 5 , -NHC(O)R 5 , -NHC(O)OR 5 , -NR 6 R 7 ,
- Cycloalkyl means a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent comprising from 3 to 20 carbon atoms, preferably from 3 to 12 carbon atoms, more preferably the cycloalkyl ring comprises from 3 to 10 The carbon atom, most preferably the cycloalkyl ring contains from 3 to 6 carbon atoms.
- Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptene
- the alkenyl group, the cyclooctyl group and the like are preferably a cyclopropyl group or a cyclohexenyl group.
- Polycyclic cycloalkyl groups include spiro, fused, and bridged cycloalkyl groups.
- Spirocycloalkyl means a polycyclic group of 5 to 20 members which shares a carbon atom (referred to as a spiro atom) between the monocyclic rings. These may contain one or more double bonds, but none of the rings are fully conjugated. ⁇ electronic system. It is preferably 6 to 14 members, more preferably 7 to 10 members.
- the spirocycloalkyl group is classified into a monospirocycloalkyl group, a bispirocycloalkyl group or a polyspirocycloalkyl group, preferably a monospirocycloalkyl group and a bispirocycloalkyl group, depending on the number of common spiro atoms between the ring and the ring.
- spirocycloalkyl groups include
- fused cycloalkyl means 5 to 20 members, each ring of the system sharing an adjacent carbon atomous all-carbon polycyclic group with other rings in the system, wherein one or more rings may contain one or more Two double bonds, but none of the rings have a fully conjugated ⁇ -electron system. It is preferably 6 to 14 members, more preferably 7 to 10 members. Depending on the number of constituent rings, it may be classified into a bicyclic, tricyclic, tetracyclic or polycyclic fused ring alkyl group, preferably a bicyclic or tricyclic ring, more preferably a 5-membered/5-membered or 5-membered/6-membered bicycloalkyl group.
- fused cycloalkyl groups include
- Bridge cycloalkyl means 5 to 20 members, any two rings sharing two carbon-free all-carbon polycyclic groups, which may contain one or more double bonds, but none of the rings have a total The ⁇ -electron system of the yoke. It is preferably 6 to 14 members, more preferably 7 to 10 members. Depending on the number of constituent rings, it may be classified into a bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl group, preferably a bicyclic ring, a tricyclic ring or a tetracyclic ring, and more preferably a bicyclic ring or a tricyclic ring.
- bridged cycloalkyl groups include
- the cycloalkyl ring may be fused to an aryl, heteroaryl or heterocyclyl ring, wherein the ring to which the parent structure is attached is a cycloalkyl group, non-limiting examples include indanyl, tetrahydronaphthalene Base, benzocycloheptyl and the like.
- the cycloalkyl group may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkanethio Base, alkylamino, halogen, sulfhydryl, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, Heterocycloalkylthio, oxo, amino, haloalkyl, hydroxyalkyl, carboxyl, carboxylate, -C(O)OR 5 , -OC(O)R 5 , -NHS(O) m R 5 , -C(O)R 5 , -NHC(O)R 5 , -NHC(O)OR 5 , -NR 6 R
- Heterocyclyl means a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent comprising from 3 to 20 ring atoms wherein one or more of the ring atoms are selected from nitrogen, oxygen or S(O) m ( Wherein m is a hetero atom of 0 to 2, but does not include a ring moiety of -OO-, -OS- or -SS-, and the remaining ring atoms are carbon. It preferably comprises from 3 to 12 ring atoms, wherein from 1 to 4 are heteroatoms, more preferably the heterocyclyl ring contains from 3 to 10 ring atoms, more preferably the heterocyclyl ring contains from 5 to 6 ring atoms.
- Non-limiting examples of monocyclic heterocyclic groups include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, pyranyl, tetrahydrofuranyl and the like.
- Polycyclic heterocyclic groups include spiro, fused, and bridged heterocyclic groups.
- “Spiroheterocyclyl” means a polycyclic heterocyclic group of 5 to 20 members in which one atom (referred to as a spiro atom) is shared between monocyclic rings, wherein one or more ring atoms are selected from nitrogen, oxygen or S(O) m A hetero atom (where m is an integer from 0 to 2), and the remaining ring atoms are carbon. These may contain one or more double bonds, but none of the rings have a fully conjugated pi-electron system. It is preferably 6 to 14 members, more preferably 7 to 10 members.
- the spirocycloalkyl group is classified into a monospiroheterocyclic group, a dispiroheterocyclic group or a polyspirocyclic group according to the number of common spiro atoms between the ring and the ring, and is preferably a monospiroheterocyclic group and a dispiroheterocyclic group. More preferably, it is 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or 5 yuan / 6-membered monospiroheterocyclic group.
- Non-limiting examples of spiroheterocyclyl groups include
- “Fused heterocyclyl” refers to 5 to 20 members, each ring of the system sharing an adjacent pair of atoms of a polycyclic heterocyclic group with other rings in the system, and one or more rings may contain one or more a bond, but none of the rings have a fully conjugated ⁇ -electron system in which one or more ring atoms are selected from nitrogen, oxygen or S(O) m (where m is an integer from 0 to 2), and the remaining ring atoms are carbon. It is preferably 6 to 14 members, more preferably 7 to 10 members.
- bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic group preferably a bicyclic or tricyclic ring, more preferably a 5-membered/5-membered or 5-membered/6-membered bicyclic fused heterocyclic group.
- fused heterocyclic groups include
- “Bridge heterocyclyl” refers to a polycyclic heterocyclic group of 5 to 14 members, any two rings sharing two atoms which are not directly bonded, these may contain one or more double bonds, but none of the rings have a complete conjugation A ⁇ -electron system in which one or more ring atoms are selected from nitrogen, oxygen or S(O) m (where m is an integer from 0 to 2), and the remaining ring atoms are carbon. It is preferably 6 to 14 members, more preferably 7 to 10 members.
- bridged heterocyclic groups include:
- the heterocyclyl ring may be fused to an aryl, heteroaryl or cycloalkyl ring wherein the ring to which the parent structure is attached is a heterocyclic group, non-limiting examples comprising:
- the heterocyclic group may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkanethio Base, alkylamino, halogen, sulfhydryl, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, Heterocycloalkylthio, oxo, amino, haloalkyl, hydroxyalkyl, carboxyl, carboxylate, -C(O)OR 5 , -OC(O)R 5 , -NHS(O) m R 5 , -C(O)R 5 , -NHC(O)R 5 , -NHC(O)OR 5 , -NR 6 R 7 ,
- Aryl means a 6 to 14 membered all-carbon monocyclic or fused polycyclic ring (i.e., a ring that shares a pair of adjacent carbon atoms) having a conjugated ⁇ -electron system, preferably 6 to 10 members, more preferably benzene.
- the base and naphthyl are most preferably phenyl.
- the aryl ring may be fused to a heteroaryl, heterocyclyl or cycloalkyl ring wherein the ring to which the parent structure is attached is an aryl ring, non-limiting examples comprising:
- the aryl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups, independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkane.
- Heteroaryl refers to a 5 to 14 membered aryl group having from 1 to 4 heteroatoms as ring atoms, the remaining ring atoms being carbon, wherein the heteroatoms include oxygen, sulfur and nitrogen. It is preferably 5 to 10 yuan.
- the heteroaryl group is preferably 5- or 6-membered, such as furyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, oxazolyl, Thiazolyl, pyrazolyl, and the like.
- the heteroaryl ring may be fused to an aryl, heterocyclic or cycloalkyl ring wherein the ring to which the parent structure is attached is a heteroaryl ring, non-limiting examples comprising:
- the heteroaryl group may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkanethio Base, alkylamino, halogen, sulfhydryl, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, Heterocycloalkylthio, amino, haloalkyl, hydroxyalkyl, carboxyl, carboxylate, -C(O)OR 5 , -OC(O)R 5 , -NHS(O) m R 5 , -C( O) R 5 , -NHC(O)R 5 , -NHC(O)OR 5 , -NR 6 R 7 , -OC(O
- Alkoxy means -O-(alkyl) and -O-(unsubstituted cycloalkyl), wherein alkyl is as defined above. Non-limiting examples include methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy, and the like.
- the alkoxy group may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, and an alkane group.
- Haloalkyl means that the alkyl group is substituted by one or more halogens, wherein the alkyl group is as defined above.
- Hydrophilicity refers to an -OH group.
- Hydroalkyl means an alkyl group substituted by a hydroxy group, wherein the alkyl group is as defined above.
- Halogen means fluoro, chloro, bromo or iodo.
- Amino means -NH 2 .
- Niro means -NO 2 .
- Benzyl refers to -CH 2 - phenyl.
- Carboxy refers to -C(O)OH.
- Carboxylic acid ester group means -C(O)O(alkyl) or (cycloalkyl) wherein alkyl, cycloalkyl are as defined above.
- amino protecting group is such that the amino group remains unchanged during the reaction of other parts of the molecule, and the amino group is protected with a group which is easily removed.
- Non-limiting examples include formyl, alkylcarbonyl, alkoxycarbonyl, benzoyl, aralkylcarbonyl, aralkoxycarbonyl, trityl, phthaloyl, N,N-dimethyl Aminoaminomethylene, substituted silyl group, and the like. These groups may be optionally substituted with from 1 to 3 substituents selected from halogen, alkoxy or nitro.
- the amino protecting group is preferably a tert-butoxycarbonyl group.
- heterocyclic group optionally substituted by an alkyl group means that an alkyl group may be, but not necessarily, present, and the description includes the case where the heterocyclic group is substituted with an alkyl group and the case where the heterocyclic group is not substituted with an alkyl group.
- Substituted refers to one or more hydrogen atoms in the group, preferably up to 5, more preferably 1 to 3, hydrogen atoms, independently of each other, substituted by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and those skilled in the art will be able to determine (by experiment or theory) substitutions that may or may not be possible without undue effort. For example, an amino group or a hydroxyl group having a free hydrogen may be unstable when combined with a carbon atom having an unsaturated (e.g., olefinic) bond.
- “Pharmaceutical composition” means a mixture comprising one or more of the compounds described herein, or a physiologically pharmaceutically acceptable salt or prodrug thereof, and other chemical components, as well as other components such as physiologically pharmaceutically acceptable carriers and Shape agent.
- the purpose of the pharmaceutical composition is to promote the administration of the organism, which facilitates the absorption of the active ingredient and thereby exerts biological activity.
- R 5 to R 7 are as defined in the compound of the formula (I).
- the compound of the formula (Ia) is subjected to a reduction reaction in the presence of a catalyst to obtain a compound of the formula (IA) or a salt thereof;
- a compound of the formula (I) or a salt thereof is subjected to a condensation reaction with a compound of the formula (IB) under basic conditions to give a compound of the formula (I);
- R c is selected from a hydroxyl group or a halogen
- the ring P, ring Q, A, B, Y, s, t, R 1 to R 4 are as defined in the formula (I).
- the compound of the formula (IIIa) is subjected to a coupling reaction with a compound of the formula (IIIb) under catalytic conditions to obtain a compound of the formula (IIIc); and the compound of the formula (IIIc) is subjected to a reduction reaction under catalytic conditions to obtain a formula (IIIA).
- a compound or a salt thereof; a compound of the formula (IIIA) or a salt thereof and a compound of the formula (IIIB) are condensed under basic conditions to give a compound of the formula (III);
- R c is selected from a hydroxyl group or a halogen
- R d is selected from halogen, preferably bromine or iodine;
- E, G and W are each independently selected from CR a , NR b , N, O or S;
- A, B, X, Y, t, R 1 , R 2 and R 4 are as defined in the formula (I).
- the compound of the formula (VIa) is subjected to a coupling reaction with a compound of the formula (IIIb) in the presence of a catalyst to obtain a compound of the formula (VIb); and the compound of the formula (VIb) is subjected to a reduction reaction in the presence of a catalyst to obtain a formula (VIA).
- a compound or a salt thereof; a compound of the formula (VIA) or a salt thereof and a compound of the formula (VIB) are subjected to a condensation reaction under basic conditions to give a compound of the formula (VI);
- R c is selected from a hydroxyl group or a halogen
- R d is selected from halogen, preferably bromine or iodine;
- A, B, X, Y, t, R 1 , R 2 , R 4 are as defined in the general formula (I);
- R b is as described in the general formula (IV).
- the compound of the formula (VIa) is subjected to a coupling reaction with a compound of the formula (VIb) in the presence of a catalyst to obtain a compound of the formula (Vb); and the compound of the formula (Vb) is subjected to a reduction reaction in the presence of a catalyst to obtain a formula (VA).
- a compound or a salt thereof; a compound of the formula (VA) or a salt thereof and a compound of the formula (VB) are subjected to a condensation reaction under basic conditions to give a compound of the formula (VII);
- R c is selected from a hydroxyl group or a halogen
- R d is selected from halogen, preferably bromine or iodine;
- A, B, X, Y, R 1 , R 2 are as defined in the general formula (I);
- R b is as defined in the general formula (IV);
- R 8 is as defined in the formula (VII).
- the reagent for basic conditions includes an organic base and an inorganic base
- the organic base includes, but not limited to, triethylamine, N,N-diisopropylethylamine, pyridine, hexamethyldiene.
- said inorganic bases including but not limited to lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium hydride, sodium carbonate
- Sodium hydrogencarbonate, potassium carbonate, potassium hydrogencarbonate or cesium carbonate preferably triethylamine.
- Catalysts include, but are not limited to, palladium on carbon, Raney nickel, tetra-triphenylphosphine palladium, palladium dichloride, palladium acetate, 1,1'-bis(dibenzylphosphine) dichlorodipentadium iron palladium or tri Dibenzylideneacetone) dipalladium.
- Condensing agents include, but are not limited to, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N'-dicyclohexylcarbodiimide, N,N'-di Propylcarbodiimide, O-benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroborate, 1-hydroxybenzotriazole, 1-hydroxy-7- Azobenzotriazole, O-benzotriazole-N,N,N',N'-tetramethyluron hexafluorophosphate, 2-(7-azobenzotriazole)-N, N,N',N'-tetramethylurea hexafluorophosphate, benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate or benzotriazole hexafluorophosphate- 1-yl
- the structure of the compound is determined by nuclear magnetic resonance (NMR) or mass spectrometry (MS).
- NMR nuclear magnetic resonance
- MS mass spectrometry
- the NMR was measured by a Bruker AVANCE-400 nuclear magnetic apparatus, and the solvent was deuterated dimethyl sulfoxide (DMSO-d 6 ), deuterated chloroform (CDCl 3 ), deuterated methanol (CD 3 OD), and the internal standard was four.
- DMSO-d 6 dimethyl sulfoxide
- CDCl 3 deuterated chloroform
- CD 3 OD deuterated methanol
- TMS Methylsilane
- chemical shifts are given in units of 10 -6 (ppm).
- the measurement of the MS was carried out using a FINNIGAN LCQAd (ESI) mass spectrometer (manufacturer: Thermo, model: Finnigan LCQ advantage MAX).
- ESI FINNIGAN LCQAd
- the HPLC was measured using an Agilent 1200 DAD high pressure liquid chromatograph (Sunfire C18 150 x 4.6 mm column) and a Waters 2695-2996 high pressure liquid chromatograph (Gimini C18 150 x 4.6 mm column).
- Thin layer chromatography silica gel plate uses Yantai Yellow Sea HSGF254 or Qingdao GF254 silica gel plate.
- the specification of silica gel plate used for thin layer chromatography (TLC) is 0.15mm ⁇ 0.2mm.
- the specification for thin layer chromatography separation and purification is 0.4mm. ⁇ 0.5mm silica gel plate.
- the known starting materials of the present invention may be synthesized by or according to methods known in the art, or may be purchased from ABCR GmbH & Co. KG, Acros Organnics, Aldrich Chemical Company, Accela ChemBio Inc, Dari Companies such as chemicals.
- An argon atmosphere or a nitrogen atmosphere means that the reaction flask is connected to an argon or nitrogen balloon having a volume of about 1 L.
- the hydrogen atmosphere means that the reaction flask is connected to a hydrogen balloon of about 1 L volume.
- the pressurized hydrogenation reaction was carried out using a Parr Model 3916EKX hydrogenation apparatus and a clear blue QL-500 type hydrogen generator or a HC2-SS type hydrogenation apparatus.
- the hydrogenation reaction is usually evacuated, charged with hydrogen, and operated three times.
- the microwave reaction used a CEM Discover-S Model 908860 microwave reactor.
- the solution in the reaction means an aqueous solution unless otherwise specified.
- the temperature of the reaction was room temperature unless otherwise specified.
- Room temperature is the most suitable reaction temperature, and the temperature range is from 20 ° C to 30 ° C.
- the progress of the reaction in the examples was monitored by thin layer chromatography (TLC).
- TLC thin layer chromatography
- the system used for the reaction was: A: dichloromethane and methanol system, B: n-hexane and ethyl acetate system, C: petroleum ether And the ethyl acetate system, D: acetone, the volume ratio of the solvent is adjusted depending on the polarity of the compound.
- the system for the eluent of the column chromatography and the system for the thin layer chromatography of the developer used for the purification of the compound include: A: dichloromethane and methanol system, B: n-hexane and ethyl acetate system, C: n-hexane and acetone
- the volume ratio of the solvent is adjusted depending on the polarity of the compound, and may be adjusted by adding a small amount of triethylamine and an acidic or alkaline reagent.
- Ethyl 5-cyano-2-(difluoromethyl)nicotinate 1c (606 mg, 2.7 mmol) was dissolved in 15 mL of ethanol and concentrated hydrochloric acid (1 mL, 37%) and palladium/carbon (180 mg, 10%) The hydrogen was replaced three times, and the reaction was stirred for 2 hours. The reaction mixture was filtered over EtOAc EtOAc (EtOAc) 99%.
- Ethyl 2-(difluoromethyl)-5-(isobutylamidomethyl)nicotinate 1e (790 mg, 2.6 mmol) was dissolved in 10 mL of 1,4-dioxane, and 5 mL of water and hydrate were added. Lithium hydroxide (291 mg, 6.9 mmol) was stirred for 16 hours. The reaction mixture was concentrated under reduced pressure. EtOAc was evaporated. EtOAc EtOAc EtOAc (EtOAc) The obtained residue was combined with EtOAc EtOAc (EtOAc md. .
- 2-Amino-3-bromo-5-nitropyridine 3b (1.0 g, 4.6 mmol), 4-fluorophenylacetylene 3a (1.24 g, 10.3 mmol), bis(triphenylphosphine)palladium dichloride (0.25) g, 0.35 mmol), cuprous iodide (7 mg, 0.35 mmol) And triethylamine (0.7 mL, 4.6 mmol) was sequentially added to 20 mL of N,N-dimethylformamide, and after the addition, the mixture was stirred uniformly, argon was replaced three times, and the reaction was stirred for 16 hours. The reaction mixture was filtered through EtOAc (EtOAc)EtOAc. The crude pyridin-2-amine 3c (1.7 g, brown solid) was used directly in the next step.
- EtOAc EtOAc
- 1-ethyl-1H-indole-5-amine 12a (50 mg, 0.31 mmol, prepared by a known method "Bioorganic & Medicinal Chemistry, 2005, 13 (10), 3531-3541”), 2-(difluoro) Methyl)-5-(isobutyrylmethyl)nicotinic acid 1f (70 mg, 0.26 mmol), O-benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroborate ( 124 mg, 0.39 mmol) and N,N-diisopropylethylamine (100 mg, 0.78 mmol) were sequentially added to 5 mL of N,N-dimethylformamide, heated to 75 ° C, and the reaction was stirred for 16 hours. The reaction mixture was concentrated under reduced pressure. EtOAcjjjjjjjjj 5-(-Isobutyrylmethyl)nicotinamide 12 (20 mg, brown solid), yield: 18.9%.
- reaction mixture was concentrated under reduced pressure and purified mjjjjjjj -N-(1-Methyl-2-(4-(trifluoromethyl)phenyl)-1H-indol-5-yl)nicotinamide 15 (4 mg, pale yellow solid), yield: 4.2 %.
- 2-(2-Chlorophenyl)-1-ethyl-1H-indole-5-amine 19c 80 mg, 0.30 mmol
- 2-(difluoromethyl)-5-((2-fluoro-2) -methylpropionamido)methyl)nicotinic acid 14b 86 mg, 0.30 mmol
- 1-ethyl-(3-dimethylaminopropyl)carbonyldiimide hydrochloride 115 mg, 0.60 mmol
- 1-Hydroxybenzotriazole 40 mg, 0.30 mmol
- triethylamine 118 mg, 1.17 mmol
- 2-(3-Chlorophenyl)-1-ethyl-1H-indole-5-amine 20c 45 mg, 0.17 mmol
- 2-(difluoromethyl)-5-((2-fluoro-2) -methylpropionamido)methyl)nicotinic acid 14b 49 mg, 0.17 mmol
- 1-ethyl-(3-dimethylaminopropyl)carbonyldiimide hydrochloride 48 mg, 0.25 mmol
- 1-Hydroxybenzotriazole 23 mg, 0.17 mmol
- triethylamine 68 mg, 0.66 mmol
- reaction liquid was evaporated under reduced pressure of ethanol, and the mixture was adjusted to pH 4 to 5 with 6M hydrochloric acid, and a large amount of solid was precipitated, and ethyl acetate (100 mL) was added thereto, and the mixture was stirred, filtered, and the filter cake was dried to give the title product 2-(difluoromethyl)- 5-((1-(Trifluoromethyl)cyclopropanecarboxamide)methyl)nicotinic acid 21c (2.0 g, white solid).
- the p-trifluoromethylaniline 24a (2.35 g, 14.56 mmol) was dissolved in 50 mL of 1,2-dichloroethane, and o-nitrobenzaldehyde 24b (2.0 g, 13.23 mmol) was added, and the reaction was stirred and stirred. An additional hour, additional sodium triacetoxyborohydride (5.6 g, 26.46 mmol) was added and the reaction was stirred for 16 h. 100 mL of dichloromethane and 100 mL of water were added to the reaction mixture, and the mixture was stirred, and the organic layer was evaporated to dryness. Benzyl)-4-(trifluoromethyl)aniline 24c (3.5 g, yellow oil), yield: 89.4%.
- Zinc powder (1.73 g, 27.04 mmol) was added to 50 mL of tetrahydrofuran, and the mixture was stirred uniformly. Titanium tetrachloride (2.57 g, 13.55 mmol) was slowly added thereto, and the mixture was heated to 70 ° C, and the reaction was stirred for 2 hours. The heating was stopped, the temperature of the reaction solution was naturally cooled to room temperature, and the pH of the reaction mixture was adjusted to 8 with triethylamine.
- N-(2-Nitrobenzyl)-4-(trifluoromethyl)aniline 24c (1.0 g, 3.38 mmol) was dissolved in 20 mL of tetrahydrofuran, added to the reaction mixture, and the mixture was stirred and stirred for 30 minutes.
- the pH of the reaction mixture was adjusted to 3 with 6M hydrochloric acid, and extracted with dichloromethane (100 mL ⁇ 3).
- the organic phase was combined, and the organic phase was dried over anhydrous sodium sulfate.
- the obtained residue was purified to purified crystalljjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjj
- reaction mixture was filtered over EtOAcjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjj
- 6-Amino-2-(4-(trifluoromethyl)phenyl)isoindolin-1-one 25c 64 mg, 0.22 mmol was dissolved in 10 mL of tetrahydrofuran, and lithium aluminum hydride (51 mg, 1.32 mmol) was added. After the addition, heat to 65 ° C, stir the reaction It should be 16 hours. 0.1 mL of a sodium hydroxide solution (15%) and 0.4 mL of water were added to the reaction solution, magnesium sulfate was added thereto, and the mixture was stirred for 5 minutes, and the filtrate was filtered, washed with ethyl acetate, and the organic layer was evaporated. The obtained residue was purified with EtOAc EtOAc (EtOAc) .
- EtOAc EtOAc
- 5-Nitroindole 30a (810 mg, 5.0 mmol) was dissolved in 10 mL of N,N-dimethylformamide, and sodium hydride (300 mg, 7.5 mmol) was added, and the ice bath was removed. The temperature of the reaction mixture was naturally raised to room temperature, and the reaction was stirred for 10 minutes, and tetrahydrofuran-3-ylmethanesulfonate 30b (1.66 g, 10.0 mmol) was added by a known method "Journal of Organic Chemistry, 2008, 73(14), 5397- 5409" was prepared), added, heated to 50 ° C, and stirred for 16 hours.
- 5-Nitroindole 30a (9.0 g, 55.3 mmol) and cesium carbonate (36.0 g, 110.6 mmol) were dissolved in 100 mL of N,N-dimethylformamide, and (R)-tetrahydrofuran-3-yl group was added.
- Sulfonate 31a (18.4 g, 110.6 mmol, prepared by a known method "Nature Chemical Biology, 2008, 4 (11), 691-699"
- the mixture was heated to 70 ° C and stirred for 16 hours. The heating was stopped, 400 mL of ice water was added to the reaction mixture, a large amount of solid was precipitated, and the mixture was filtered.
- 5-Nitroindole 30a (5.0 g, 30.8 mmol) and cesium carbonate (20.0 g, 61.3 mmol) were dissolved in 70 mL of N,N-dimethylformamide, and (S)-tetrahydrofuran-3-yl group was added.
- the sulfonate 32a (10.0 g, 60.2 mmol, obtained by a known method "Nature Chemical Biology, 2008, 4 (11), 691-699" was added, heated to 70 ° C, and stirred for 16 hours.
- 2-(3-Chlorophenyl)-1-methyl-1H-indole-5-amine 33b (269 mg, 1.05 mmol), 2-(difluoromethyl)-5-((2-fluoro-2) -methylpropionamido)methyl)nicotinic acid 14b (305 mg, 1.05 mmol), 1-ethyl-(3-dimethylaminopropyl)carbonyldiimide hydrochloride (302 mg, 1.58 mmol), 1-Hydroxybenzotriazole (14 mg, 0.10 mmol) and N,N-diisopropylethylamine (271 mg, 2.1 mmol) were sequentially added to 10 mL of N,N-dimethylformamide, and the mixture was stirred and stirred.
- 6-Chloropyridin-3-amine 35a (1 g, 7.78 mmol) was dissolved in 20 mL of N,N-dimethylformamide, and N-iodosuccinimide (2.27 g, 10.11 mmol) was added at room temperature. The reaction was carried out for 16 hours. The reaction mixture was concentrated under reduced vacuoljjjjjjjjj %.
- 6-Chloro-2-iodopyridin-3-amine 35b (1.37 g, 5.38 mmol), 3-chlorophenylacetylene (882 mg, 6.46 mmol), bis(triphenylphosphine)palladium dichloride (378 mg, 0.54 mmol) ), cuprous iodide (205 mg, 1.08 mmol), N,N-diisopropylethylamine (1.39 g, 10.76 mmol) and 10 mL of N,N-dimethylformamide in a reaction flask, argon atmosphere The reaction was stirred at 100 ° C for 16 hours.
- the reaction mixture was concentrated under reduced vacuoljjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjj
- 6-Chloro-2-((3-chlorophenyl)ethynyl)pyridin-3-amine 35c (871 mg, 3.32 mmol), potassium t-butoxide (746 mg, 6.64 mmol) and 20 mL of N,N-dimethyl
- the carboxamide was placed in a reaction flask, and the reaction was stirred at 70 ° C for 16 hours.
- the reaction mixture was concentrated under reduced vacuol ⁇
- the crude pyridine 35d (1.17 g, yellow solid) was used directly in the next step.
- 5-Amino-2-nitropyridine 36a (1 g, 7.2 mmol), potassium iodate (770 mg, 3.6 mmol) and potassium iodide (1.2 g, 7.2 mmol) were sequentially added to 30 mL of sulfuric acid (2N), added, heated The reaction was stirred at 80 ° C for 16 hours. The heating was stopped, the reaction solution was naturally cooled to room temperature, and a 2N sodium hydroxide solution was added dropwise to adjust the pH of the reaction mixture to 10, and a large amount of solid was precipitated. Filtration, the filter cake was washed with water and dried to give the title product 4- ⁇ /RTI> ⁇ RTIgt; ⁇ /RTI> ⁇ RTIgt;
- reaction solution was evaporated under reduced pressure of 1,4-dioxane, and 6 M hydrochloric acid was added dropwise to pH 4 to 5, and a large white solid was precipitated, and 30 mL of ethyl acetate was added to the reaction mixture, and the mixture was stirred and filtered. The filter cake was collected, the organic layer was separated, and the organic layer was dried over anhydrous magnesium sulfate.
- -((1-Methylcyclopropionamido)methyl)nicotinic acid 42c (1 g, white solid), yield: 91.7%.
- 2-Amino-3-iodo-5-nitropyridine 44b 300 mg, 1.13 mmol
- 4-chlorophenylacetylene 44a 325 mg, 2.38 mmol
- bis(triphenylphosphine)palladium dichloride 40 mg, 56.5 Molmol
- cuprous iodide 11 mg, 56.5 ⁇ mol
- triethylamine 1.6 mL, 11.3 mmol
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
Description
实施例编号 | IC50(nM) |
1 | 8.26 |
5 | 21.97 |
7 | 6.02 |
8 | 3.88 |
9 | 15.64 |
10 | 11.15 |
11 | 5.14 |
13 | 7.43 |
14 | 4.59 |
15 | 23.44 |
16 | 9.31 |
17 | 2.68 |
18 | 5.15 |
19 | 8.12 |
20 | 3.54 |
21 | 8.24 |
22 | 6.69 |
23 | 4.73 |
24 | 17.22 |
25 | 11.86 |
26 | 3.38 |
27 | 4.77 |
30 | 2.99 |
31 | 2.95 |
30 | 1.73 |
31 | 4.12 |
32 | 2.24 |
33 | 5.33 |
34 | 7.75 |
35 | 4.07 |
36 | 4.19 |
37 | 6.46 |
38 | 5.43 |
39 | 3.68 |
40 | 22.44 |
41 | 25.65 |
42 | 7.21 |
43 | 15.96 |
45 | 49.39 |
46 | 2.71 |
47 | 5.72 |
48 | 3.58 |
49 | 8.29 |
54 | 47.09 |
55 | 29.78 |
56 | 7.74 |
57 | 6.75 |
58 | 8.51 |
59 | 1.18 |
实施例编号 | IC50(nM) |
11 | 210.60 |
14 | 91.18 |
18 | 152.50 |
20 | 74.73 |
32 | 16.86 |
33 | 107.60 |
35 | 39.88 |
36 | 137.30 |
37 | 141.10 |
实施例编号 | IC50(nM) |
1 | 3.55 |
4 | 26.87 |
5 | 12.40 |
6 | 68.10 |
7 | 10.44 |
8 | 19.15 |
9 | 11.85 |
10 | 12.31 |
11 | 16.30 |
13 | 16.67 |
14 | 20.46 |
15 | 33.31 |
16 | 26.18 |
17 | 12.14 |
18 | 17.19 |
19 | 42.60 |
20 | 12.57 |
21 | 57.42 |
22 | 38.80 |
23 | 49.02 |
24 | 45.65 |
25 | 47.63 |
26 | 46.05 |
27 | 13.44 |
30 | 19.17 |
31 | 32.39 |
30 | 7.18 |
31 | 17.00 |
32 | 18.83 |
33 | 12.78 |
34 | 12.21 |
35 | 31.56 |
36 | 13.22 |
37 | 22.45 |
38 | 42.85 |
39 | 30.53 |
40 | 16.87 |
43 | 58.18 |
45 | 25.91 |
46 | 24.70 |
47 | 18.93 |
48 | 14.13 |
49 | 23.97 |
52 | 55.20 |
54 | 58.53 |
56 | 27.49 |
57 | 6.22 |
58 | 2.18 |
59 | 20.52 |
Claims (18)
- 一种通式(I)所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐:其中:环P选自5元杂芳基或5元杂环基;环Q选自芳基或杂芳基;A、B或Y选自-CH-或N;R1选自烷基或环烷基,其中所述的烷基或环烷基任选进一步被一个或多个选自烷基、卤素或卤代烷基的取代基所取代;R2选自卤素或卤代烷基;各个R3相同或不同,其各自独立地选自氢原子、卤素、烷氧基、氰基、硝基、烷基、环烷基、杂环基、氧代、-C(O)OR5、-OC(O)R5、-NHS(O)mR5、-C(O)R5、-NHC(O)R5、-NHC(O)OR5、-NR6R7、-OC(O)NR6R7或-C(O)NR6R7,其中所述的烷基、环烷基或杂环基任选进一步被一个或多个选自卤素、羟基、烷氧基、氰基、硝基、烷基、卤代烷基、羟烷基、环烷基、杂环基、芳基、杂芳基、-C(O)OR5、-OC(O)R5、-NHS(O)mR5、-C(O)R5、-NHC(O)R5、-NHC(O)OR5、-NR6R7、-OC(O)NR6R7或-C(O)NR6R7的取代基所取代;R4选自芳基或杂芳基,其中所述的芳基或杂芳基任选进一步被一个或多个选自卤素、烷氧基、羟基、氰基、硝基、烷基、卤代烷基、羟烷基、环烷基、杂环基、芳基、杂芳基、-C(O)OR5、-OC(O)R5、-NHS(O)mR5、-C(O)R5、-NHC(O)R5、-NHC(O)OR5、-NR6R7、-OC(O)NR6R7或-C(O)NR6R7的取代基所取代,其中所述的卤代烷基优选为三氟甲基;R5选自烷基、烯基、炔基、环烷基、杂环基、芳基或杂芳基,其中所述的烷基、环烷基、芳基或杂芳基任选进一步被一个或多个选自烷基、卤素、羟基、羟烷基、烷氧基、环烷基、杂环基、芳基、杂芳基、羧酸或羧酸酯的取代基所取代;R6或R7各自独立地选自氢原子、烷基、烷氧基、环烷基、杂环基、芳基或杂芳基,其中所述的烷基、烷氧基、环烷基、杂环基、芳基或杂芳基各自独立地任选进一步被一个或多个选自烷基、卤素、羟基、羟烷基、烷氧基、环烷基、杂环 基、芳基、杂芳基、羧酸或羧酸酯的取代基所取代;或者,R6或R7与相连接的氮原子一起形成杂环基,其中所述的杂环基内含有一个或多个N、O或S(O)m杂原子,并且所述杂环基任选进一步被一个或多个选自烷基、卤素、羟基、烷氧基、羟烷基、环烷基、杂环基、芳基、杂芳基、羧酸或羧酸酯的取代基所取代;m为0、1或2;s为0~3的整数;t为0或1。
- 根据权利要求1所述的通式(I)所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其为通式(III)、(IV)或(V)所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐:其中:X选自-CH-或N;E、G和W各自独立地选自CRa、NRb、N、O或S;Ra和Rb各自独立地选自氢原子、卤素、烷氧基、氰基、硝基、烷基、环烷基、杂环基、-C(O)OR5、-OC(O)R5、-NHS(O)mR5、-C(O)R5、-NHC(O)R5、-NHC(O)OR5、-NR6R7、-OC(O)NR6R7或-C(O)NR6R7,其中所述的烷基、环烷基或杂环基任选进一步被一个或多个选卤素、羟基、烷氧基、氰基、硝基、烷基、卤代烷基、羟烷基、环烷基、杂环基、芳基、杂芳基、-C(O)OR5、-OC(O)R5、-NHS(O)mR5、-C(O)R5、-NHC(O)R5、-NHC(O)OR5、-NR6R7、-OC(O)NR6R7或-C(O)NR6R7的取代基所取代;且A、B、Y、t、R1~R2、R4~R7的定义如权利要求1中所述。
- 根据权利要求1所述的通式(I)所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其为通式(VI)所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐:其中:X选自-CH-或N;Rb选自氢原子、卤素、烷氧基、氰基、硝基、烷基、环烷基、杂环基、-C(O)OR5、-OC(O)R5、-NHS(O)mR5、-C(O)R5、-NHC(O)R5、-NHC(O)OR5、-NR6R7、-OC(O)NR6R7或-C(O)NR6R7,其中所述的烷基、环烷基或杂环基任选进一步被一个或多个选自卤素、羟基、烷氧基、氰基、硝基、烷基、卤代烷基、羟烷基、环烷基、杂环基、芳基、杂芳基、-C(O)OR5、-OC(O)R5、-NHS(O)mR5、-C(O)R5、-NHC(O)R5、 -NHC(O)OR5、-NR6R7、-OC(O)NR6R7或-C(O)NR6R7的取代基所取代;且A、B、Y、t、R1~R2、R4~R7的定义如权利要求1中所述。
- 根据权利要求1所述的通式(I)所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其为通式(VII)所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐:其中:X选自-CH-或N;Rb选自氢原子、卤素、烷氧基、氰基、硝基、烷基、环烷基、杂环基、-C(O)OR5、-OC(O)R5、-NHS(O)mR5、-C(O)R5、-NHC(O)R5、-NHC(O)OR5、-NR6R7、-OC(O)NR6R7或-C(O)NR6R7,其中所述的烷基、环烷基或杂环基任选进一步被一个或多个选自卤素、羟基、烷氧基、氰基、硝基、烷基、卤代烷基、羟烷基、环烷基、杂环基、芳基、杂芳基、-C(O)OR5、-OC(O)R5、-NHS(O)mR5、-C(O)R5、-NHC(O)R5、-NHC(O)OR5、-NR6R7、-OC(O)NR6R7或-C(O)NR6R7的取代基所取代;R8选自卤素、烷氧基、羟基、氰基、硝基、烷基、卤代烷基、羟烷基、环烷基、杂环基、芳基、杂芳基、-C(O)OR5、-OC(O)R5、-NHS(O)mR5、-C(O)R5、-NHC(O)R5、-NHC(O)OR5、-NR6R7、-OC(O)NR6R7或-C(O)NR6R7的取代基所取代,其中所述的卤代烷基优选为三氟甲基;且A、B、Y、R1~R2、R5~R7的定义如权利要求1中所述。
- 根据权利要求1~5任一项所述的通式(I)所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中A、B和Y选自-CH-。
- 根据权利要求1~5任一项所述的通式(I)所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中A、B和Y之一为N,其余两个为-CH-。
- 一种通式(IA)所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,包括如下基团:其中:R3选自氢原子、烷基或杂环基,其中所述的烷基任选进一步被一个或多个选自烷氧基或杂环基的取代基所取代;R4选自芳基或杂芳基,其中所述的芳基或杂芳基任选进一步被一个或多个选自卤素或卤代烷基的取代基所取代,其中所述的卤代烷基优选为三氟甲基;R4优选为苯基,其中所述的苯基进一步被一个卤素或卤代烷基的取代基所取代;t为1;条件是:当通式(IA)为R3选自氢原子或烷基,其中所述的烷基任选进一步被一个或多个选自烷氧基或杂环基的取代基所取代;R4选自苯基,其中所述的苯基进一步被一个卤代烷基的取代基所取代;其中所述的卤代烷基优选为三氟甲基;或者,R3选自杂环基;R4选自为苯基,其中所述的苯基进一步被一个卤素或卤代烷基的取代基所取代。
- 一种药物组合物,所述药物组合物含有治疗有效量的根据权利要求1所述的通式(I)所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、或其可药用的盐及药学上可接受的载体、稀释剂或赋形剂。
- 根据权利要求1-10任意一项所述的通式(I)所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,或根据权利要求15所述的药物组合物在制备治疗微粒体前列腺素E合成酶-1介导的疾病的药物中的用途。
- 根据权利要求1-10任意一项所述的通式(I)所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,或根据权利要求15所述的药物组合物在制备抑制微粒体前列腺素E合成酶-1的药物中的用途。
- 根据权利要求1-10任意一项所述的通式(I)所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用盐,或根据权利要求15所述的药物组合物在制备治疗和/或预防疾病或病症的药物中的用途,所述疾病或病症选自炎症、疼痛、癌症、糖尿病和糖尿病并发症或神经变性病症,优选为炎症或疼痛,更优选为骨关节炎、类风湿性关节炎、粘液囊炎、强直性脊柱炎、或与其中任一者相关的疼痛。
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/303,704 US10081629B2 (en) | 2014-04-14 | 2015-03-31 | Amide derivatives and pharmaceutically acceptable salts thereof, preparation method thereof and medicinal application thereof |
CA2944357A CA2944357A1 (en) | 2014-04-14 | 2015-03-31 | Amide derivatives and pharmaceutically acceptable salts thereof, preparation method thereof and medicinal application thereof |
MX2016013529A MX368504B (es) | 2014-04-14 | 2015-03-31 | Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos. |
BR112016023679A BR112016023679A2 (pt) | 2014-04-14 | 2015-03-31 | derivados de amida e sais farmaceuticamente aceitáveis dos mesmos, método de preparação dos mesmos e aplicação medicinal dos mesmos |
ES15779882T ES2838625T3 (es) | 2014-04-14 | 2015-03-31 | Derivados de amida y sales farmacéuticamente aceptables de los mismos, su método de preparación y aplicación médica de los mismos |
RU2016143333A RU2681537C2 (ru) | 2014-04-14 | 2015-03-31 | Амидные производные и их фармацевтически приемлемые соли, способ их получения и медицинское применение |
JP2016561312A JP6688445B2 (ja) | 2014-04-14 | 2015-03-31 | アミド誘導体およびそれらの薬学的に許容される塩、それらの製造方法およびそれらの医薬応用 |
KR1020167031674A KR20160134865A (ko) | 2014-04-14 | 2015-03-31 | 아미드 유도체 및 이의 약제학적으로 허용되는 염, 이의 제조방법 및 이의 의학적 적용 |
CN201580002234.2A CN105636951B (zh) | 2014-04-14 | 2015-03-31 | 酰胺类衍生物及其可药用盐、其制备方法及其在医药上的应用 |
AU2015246577A AU2015246577B2 (en) | 2014-04-14 | 2015-03-31 | Amide derivatives and pharmaceutically acceptable salts thereof, preparation method therefor and medicinal application thereof |
EP15779882.8A EP3133068B1 (en) | 2014-04-14 | 2015-03-31 | Amide derivatives and pharmaceutically acceptable salts thereof, preparation method therefor and medicinal application thereof |
DK15779882.8T DK3133068T3 (da) | 2014-04-14 | 2015-03-31 | Amidderivater og farmaceutisk acceptable salte deraf, fremgangsmåde til fremstilling deraf og medicinske anvendelser deraf |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410148152 | 2014-04-14 | ||
CN201410148152.6 | 2014-04-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015158204A1 true WO2015158204A1 (zh) | 2015-10-22 |
Family
ID=54323472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2015/075531 WO2015158204A1 (zh) | 2014-04-14 | 2015-03-31 | 酰胺类衍生物及其可药用盐、其制备方法及其在医药上的应用 |
Country Status (16)
Country | Link |
---|---|
US (1) | US10081629B2 (zh) |
EP (1) | EP3133068B1 (zh) |
JP (1) | JP6688445B2 (zh) |
KR (1) | KR20160134865A (zh) |
CN (1) | CN105636951B (zh) |
AU (1) | AU2015246577B2 (zh) |
BR (1) | BR112016023679A2 (zh) |
CA (1) | CA2944357A1 (zh) |
DK (1) | DK3133068T3 (zh) |
ES (1) | ES2838625T3 (zh) |
HU (1) | HUE052925T2 (zh) |
MX (1) | MX368504B (zh) |
PT (1) | PT3133068T (zh) |
RU (1) | RU2681537C2 (zh) |
TW (1) | TWI714527B (zh) |
WO (1) | WO2015158204A1 (zh) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019510079A (ja) * | 2016-02-25 | 2019-04-11 | ジェシンタ・ファーマ・アーベー | 血管収縮を特徴とする疾患を治療する方法 |
WO2019101826A1 (en) | 2017-11-22 | 2019-05-31 | Khondrion Ip B.V. | Compounds as mpges-1 inhibitors |
WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
WO2021076908A1 (en) | 2019-10-18 | 2021-04-22 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
WO2021087064A1 (en) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
WO2021096860A1 (en) | 2019-11-12 | 2021-05-20 | Gilead Sciences, Inc. | Mcl1 inhibitors |
WO2021130638A1 (en) | 2019-12-24 | 2021-07-01 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
WO2021163064A2 (en) | 2020-02-14 | 2021-08-19 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
WO2021222522A1 (en) | 2020-05-01 | 2021-11-04 | Gilead Sciences, Inc. | Cd73 inhibiting 2,4-dioxopyrimidine compounds |
CN114302874A (zh) * | 2019-08-26 | 2022-04-08 | 国际药品株式会社 | 吲哚甲酰胺衍生物和包含吲哚甲酰胺衍生物的药物组合物 |
WO2022221304A1 (en) | 2021-04-14 | 2022-10-20 | Gilead Sciences, Inc. | CO-INHIBITION OF CD47/SIRPα BINDING AND NEDD8-ACTIVATING ENZYME E1 REGULATORY SUBUNIT FOR THE TREATMENT OF CANCER |
WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023127883A1 (ja) * | 2021-12-28 | 2023-07-06 | 日本新薬株式会社 | インダゾール化合物及び医薬 |
WO2023147418A1 (en) | 2022-01-28 | 2023-08-03 | Gilead Sciences, Inc. | Parp7 inhibitors |
EP4245756A1 (en) | 2022-03-17 | 2023-09-20 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023183817A1 (en) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
WO2023196784A1 (en) | 2022-04-05 | 2023-10-12 | Gilead Sciences, Inc. | Combinations of antibody therapies for treating colorectal cancer |
WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114249680B (zh) * | 2022-01-10 | 2022-12-27 | 深圳市乐土生物医药有限公司 | 一种吲哚类衍生物及其合成方法与用途 |
WO2023146846A1 (en) * | 2022-01-25 | 2023-08-03 | University Of Houston System | Use of non-steroidal anti-inflammatory compounds for treatment of inflammation |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101490000A (zh) * | 2006-07-14 | 2009-07-22 | 方济各安吉利克化学联合股份有限公司 | 作为npges-1抑制剂的2-芳基吲哚衍生物 |
WO2013038308A1 (en) * | 2011-09-15 | 2013-03-21 | Glenmark Pharmaceuticals S.A. | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS mPGES-1 INHIBITORS |
WO2013072825A1 (en) * | 2011-11-16 | 2013-05-23 | Glenmark Pharmaceuticals S.A. | Phtalazinone derivatives as mpegs -1 inhibitors |
WO2013118071A1 (en) * | 2012-02-09 | 2013-08-15 | Glenmark Pharmaceuticals S.A. | BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE720261A (zh) * | 1967-09-01 | 1969-02-28 | ||
JP2000143635A (ja) * | 1998-06-10 | 2000-05-26 | Takeda Chem Ind Ltd | 血管新生阻害剤 |
CN1156445C (zh) * | 1999-06-10 | 2004-07-07 | 沃尼尔·朗伯公司 | 采用二氢异吲哚衍生物抑制淀粉样蛋白聚集和使淀粉样蛋白沉积成像的方法 |
ITTO20040125A1 (it) * | 2004-03-01 | 2004-06-01 | Rotta Research Lab | Nuove amidine eterocicliche inibitrici la produzione di ossido d'azoto (no) ad attivita' antinfiammatoria ed analgesica |
EP1945622B1 (en) * | 2005-10-11 | 2011-12-28 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Isotopically-labeled benzofuran compounds as imagingagents for amyloidogenic proteins |
BRPI0707719A2 (pt) * | 2006-02-10 | 2011-05-10 | Summit Corp Plc | uso de um composto ou de um sal farmaceuticamente aceitÁvel do mesmo |
PE20090510A1 (es) * | 2007-08-03 | 2009-05-22 | Summit Corp Plc | Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenne |
EP2078711A1 (en) * | 2007-12-28 | 2009-07-15 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. | (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor |
EP2491007B1 (en) * | 2009-10-23 | 2013-09-25 | Boehringer Ingelheim International GmbH | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
JP2011168515A (ja) * | 2010-02-17 | 2011-09-01 | Kowa Co | エリスロポエチン産生促進作用を有する2−アリールベンゾオキサゾール化合物 |
AR084174A1 (es) | 2010-12-21 | 2013-04-24 | Lilly Co Eli | Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica |
AR086254A1 (es) | 2011-05-26 | 2013-11-27 | Lilly Co Eli | Derivados de imidazol utiles para el tratamiento de artritis |
JP5482745B2 (ja) * | 2011-08-10 | 2014-05-07 | 株式会社デンソー | 炭化珪素半導体装置およびその製造方法 |
WO2014069510A1 (ja) * | 2012-10-31 | 2014-05-08 | 富山化学工業株式会社 | 新規アミン誘導体またはその塩 |
FR3000493A1 (fr) * | 2012-12-28 | 2014-07-04 | Oribase Pharma | Nouveaux inhibiteurs de proteines kinases |
FR3000494B1 (fr) * | 2012-12-28 | 2015-08-21 | Oribase Pharma | Nouveaux derives d'azaindoles en tant qu'inhibiteurs de proteines kinases |
WO2014167444A1 (en) * | 2013-04-08 | 2014-10-16 | Glenmark Pharmaceuticals S.A. | SUBSTITUTED BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS |
WO2016090079A1 (en) * | 2014-12-05 | 2016-06-09 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
-
2015
- 2015-03-31 WO PCT/CN2015/075531 patent/WO2015158204A1/zh active Application Filing
- 2015-03-31 ES ES15779882T patent/ES2838625T3/es active Active
- 2015-03-31 EP EP15779882.8A patent/EP3133068B1/en active Active
- 2015-03-31 JP JP2016561312A patent/JP6688445B2/ja not_active Expired - Fee Related
- 2015-03-31 PT PT157798828T patent/PT3133068T/pt unknown
- 2015-03-31 US US15/303,704 patent/US10081629B2/en not_active Expired - Fee Related
- 2015-03-31 CN CN201580002234.2A patent/CN105636951B/zh active Active
- 2015-03-31 BR BR112016023679A patent/BR112016023679A2/pt not_active IP Right Cessation
- 2015-03-31 RU RU2016143333A patent/RU2681537C2/ru active
- 2015-03-31 AU AU2015246577A patent/AU2015246577B2/en not_active Ceased
- 2015-03-31 DK DK15779882.8T patent/DK3133068T3/da active
- 2015-03-31 KR KR1020167031674A patent/KR20160134865A/ko not_active Application Discontinuation
- 2015-03-31 CA CA2944357A patent/CA2944357A1/en not_active Abandoned
- 2015-03-31 MX MX2016013529A patent/MX368504B/es active IP Right Grant
- 2015-03-31 HU HUE15779882A patent/HUE052925T2/hu unknown
- 2015-04-13 TW TW104111766A patent/TWI714527B/zh active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101490000A (zh) * | 2006-07-14 | 2009-07-22 | 方济各安吉利克化学联合股份有限公司 | 作为npges-1抑制剂的2-芳基吲哚衍生物 |
WO2013038308A1 (en) * | 2011-09-15 | 2013-03-21 | Glenmark Pharmaceuticals S.A. | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS mPGES-1 INHIBITORS |
WO2013072825A1 (en) * | 2011-11-16 | 2013-05-23 | Glenmark Pharmaceuticals S.A. | Phtalazinone derivatives as mpegs -1 inhibitors |
WO2013118071A1 (en) * | 2012-02-09 | 2013-08-15 | Glenmark Pharmaceuticals S.A. | BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS |
Non-Patent Citations (1)
Title |
---|
See also references of EP3133068A4 * |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019510079A (ja) * | 2016-02-25 | 2019-04-11 | ジェシンタ・ファーマ・アーベー | 血管収縮を特徴とする疾患を治療する方法 |
WO2019101826A1 (en) | 2017-11-22 | 2019-05-31 | Khondrion Ip B.V. | Compounds as mpges-1 inhibitors |
US11672787B2 (en) | 2017-11-22 | 2023-06-13 | Khondrion Ip B.V. | Compounds as mPGES-1 inhibitors |
WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
CN114302874A (zh) * | 2019-08-26 | 2022-04-08 | 国际药品株式会社 | 吲哚甲酰胺衍生物和包含吲哚甲酰胺衍生物的药物组合物 |
WO2021076908A1 (en) | 2019-10-18 | 2021-04-22 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
EP4349413A2 (en) | 2019-10-18 | 2024-04-10 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
WO2021087064A1 (en) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
WO2021096860A1 (en) | 2019-11-12 | 2021-05-20 | Gilead Sciences, Inc. | Mcl1 inhibitors |
WO2021130638A1 (en) | 2019-12-24 | 2021-07-01 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
WO2021163064A2 (en) | 2020-02-14 | 2021-08-19 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
WO2021222522A1 (en) | 2020-05-01 | 2021-11-04 | Gilead Sciences, Inc. | Cd73 inhibiting 2,4-dioxopyrimidine compounds |
WO2022221304A1 (en) | 2021-04-14 | 2022-10-20 | Gilead Sciences, Inc. | CO-INHIBITION OF CD47/SIRPα BINDING AND NEDD8-ACTIVATING ENZYME E1 REGULATORY SUBUNIT FOR THE TREATMENT OF CANCER |
WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023127883A1 (ja) * | 2021-12-28 | 2023-07-06 | 日本新薬株式会社 | インダゾール化合物及び医薬 |
WO2023147418A1 (en) | 2022-01-28 | 2023-08-03 | Gilead Sciences, Inc. | Parp7 inhibitors |
EP4245756A1 (en) | 2022-03-17 | 2023-09-20 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023183817A1 (en) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
WO2023196784A1 (en) | 2022-04-05 | 2023-10-12 | Gilead Sciences, Inc. | Combinations of antibody therapies for treating colorectal cancer |
WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
Also Published As
Publication number | Publication date |
---|---|
TWI714527B (zh) | 2021-01-01 |
RU2016143333A3 (zh) | 2018-10-26 |
RU2681537C2 (ru) | 2019-03-07 |
CN105636951A (zh) | 2016-06-01 |
TW201612158A (en) | 2016-04-01 |
BR112016023679A2 (pt) | 2017-08-15 |
US20170037044A1 (en) | 2017-02-09 |
US10081629B2 (en) | 2018-09-25 |
HUE052925T2 (hu) | 2021-05-28 |
RU2016143333A (ru) | 2018-05-17 |
EP3133068A4 (en) | 2018-02-21 |
JP6688445B2 (ja) | 2020-04-28 |
AU2015246577A1 (en) | 2016-11-10 |
MX368504B (es) | 2019-10-04 |
CA2944357A1 (en) | 2015-10-22 |
ES2838625T3 (es) | 2021-07-02 |
PT3133068T (pt) | 2021-01-06 |
EP3133068B1 (en) | 2020-11-25 |
EP3133068A1 (en) | 2017-02-22 |
JP2017513828A (ja) | 2017-06-01 |
AU2015246577B2 (en) | 2019-10-03 |
DK3133068T3 (da) | 2021-01-11 |
MX2016013529A (es) | 2017-05-09 |
CN105636951B (zh) | 2018-05-15 |
KR20160134865A (ko) | 2016-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015158204A1 (zh) | 酰胺类衍生物及其可药用盐、其制备方法及其在医药上的应用 | |
JP6552061B2 (ja) | 代謝型グルタミン酸受容体の負のアロステリックモジュレーター(nams)とその使用 | |
JP6050241B2 (ja) | 神経変性疾患の治療のための新規化合物 | |
EP1820504A1 (en) | Imine compound | |
US20070078121A1 (en) | Enzyme modulators and treatments | |
JP5800814B2 (ja) | 複素環化合物およびその用途 | |
TW200803855A (en) | Quinolones useful as inducible nitric oxide synthase inhibitors | |
JPWO2009157196A1 (ja) | アミド化合物 | |
WO2009107391A1 (ja) | 6員芳香環含有化合物 | |
JP2007514759A (ja) | キナーゼ阻害剤 | |
SK19252001A3 (sk) | Indazolové zlúčeniny, farmaceutické prípravky na inhibíciu proteínkináz a ich použitie | |
KR20140002709A (ko) | Faah 저해제 | |
JP2016539989A (ja) | Rorガンマモジュレータとして有用な二環式ヘテロアリールインドール同族体 | |
WO2018186365A1 (ja) | リードスルー誘導剤およびその医薬用途 | |
KR20160098909A (ko) | 소디움 채널 차단제 | |
JP5800813B2 (ja) | 複素環化合物 | |
CN115768761A (zh) | 新颖苯并咪唑衍生物 | |
KR20150132345A (ko) | Hdac 저해제 | |
JP2001139575A (ja) | 新規ピラゾロピリジン誘導体 | |
TW200914457A (en) | Pyrimidodiazepinone derivative | |
JP3012338B2 (ja) | アリールおよびヘテロアリールアルコキシナフタレン誘導体 | |
CN112969698A (zh) | 化学化合物 | |
JP6052673B2 (ja) | ピラゾール誘導体またはその塩ならびにそれらを含有する医薬組成物 | |
KR101741956B1 (ko) | 신규 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물 | |
TW202417429A (zh) | 用於抑制yap-tead交互作用的新穎雜雙環化合物及包含其之藥學組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15779882 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2944357 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2016561312 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15303704 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2016/013529 Country of ref document: MX |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016023679 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2015246577 Country of ref document: AU Date of ref document: 20150331 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20167031674 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015779882 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015779882 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016143333 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112016023679 Country of ref document: BR Kind code of ref document: A2 Effective date: 20161011 |